•
Jun 30, 2021
Mersana Q2 2021 Earnings Report
Mersana reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Key Takeaways
Mersana Therapeutics reported cash and cash equivalents of $227.4 million as of June 30, 2021. Net cash used in operating activities in the second quarter of 2021 was $34.5 million. The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.
Upifitamab Rilsodotin (UpRi) is a first-in-class Dolaflexin ADC targeting NaPi2b.
XMT-1592 is the first Dolasynthen ADC targeting NaPi2b.
XMT-1660 is a first-in-class Dolasynthen ADC targeting B7-H4.
XMT-2056 is the first Immunosynthen STING-agonist ADC.
Mersana
Mersana
Forward Guidance
The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.